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ABSTRACT 
Weak and ineffective antitumor cytotoxic T lymphocyte (CTL) responses can be 
rescued by immunomodulatory monoclonal antibodies (mAbs) targeting PD-1 or 
CD137. Using Batf3
-/-
 mice, which are defective for cross-presentation of cell-
associated antigens, we show that Batf3-dependent dendritic cells (DCs) are essential 
for the response to therapy with anti-CD137 or anti-PD-1 mAbs. Batf3
-/-
 mice failed to 
prime an endogenous CTL-mediated immune response toward tumor-associated 
antigens, including neoantigens. As a result, the immunomodulatory mAbs could not 
amplify any therapeutically functional immune response in these mice. Moreover, 
administration of systemic sFlt3L and local poly-ICLC enhanced DC-mediated cross-
priming and synergized with anti-CD137- and anti-PD-1-mediated immunostimulation 
in tumor therapy against B16-OVA-derived melanomas, whereas this function was lost 
in Batf3
-/-
 mice. These experiments show that cross-priming of tumor antigens by Flt3L- 
and Batf3-dependent DCs is crucial to the efficacy of immunostimulatory mAbs and 
represents a very attractive point of intervention to enhance their clinical antitumor 
effects. 
 
Statement of significance 
Immunotherapy with immunostimulatory monoclonal antibodies (mAbs) is currently 
achieving durable clinical responses in different types of cancer. We show that cross-
priming of tumor antigens by Batf3-dependent dendritic cells is a key limiting factor 
that can be exploited to enhance the antitumor efficacy of anti-PD-1 and anti-CD137 
immunostimulatory mAbs. 
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INTRODUCTION 
Tumor cells are antigenic as a result of abundant mutated sequences in their exomes (1). 
However, they are poorly immunogenic to prime cytotoxic T lymphocyte (CTL) 
responses because antigen presentation takes place in the absence of appropriate 
costimulation, and in a strongly immunosuppressive environment (2). The immune 
response to cell-associated antigens requires the interplay of specialized and 
professional antigen presenting cells called dendritic cells (DCs). Among the variety of 
DC subsets, certain DCs excel at redirecting cell-associated phagocytosed proteins to 
the MHC class I antigen presentation pathway (3), a process termed cross-presentation, 
or cross-priming if it results in CD8 T cell activation. There is evidence that tumor 
antigens are efficiently cross-presented in vivo (4). 
 Two DC subsets have been identified in mice as the most efficient at cross-
priming in vivo: lymphoid-tissue resident CD11c
+ 
CD8
+ 
Clec9a/DNGR-1
+ 
XCR1
+
 
DCs and migratory CD11c
+ 
CD103
+ 
Clec9a/DNGR-1
+ 
XCR1
+
 DCs (5). Differentiation 
of both DC subsets shows an absolute requirement for Flt3L, and is largely affected by 
the absence of Batf3 (6). Notably, the absence of Batf3 not only impairs numbers, but 
also functional responses in the remaining CD11c
+
 Clec9a/DNGR1
+
 XCR1
+
 DCs, such 
as cell-associated cross-presentation or IL-12 production (7, 8). Notably, Batf3
-/-
 mice 
show impaired immunity against syngeneic immunogenic fibrosarcomas (6) and 
regulate T cell infiltration in models of melanoma (9). However, other Batf3-
independent DC subsets mediate the immune system-dependent antitumor activity of 
anthracyclines (10) and mediate tumor rejection under activating conditions in Batf3-
deficient mice (11). Recent reports further support an important role for intratumoral 
Batf3-dependent CD103
+
 DCs in priming a CTL response through IL-12 production 
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(12, 13). In humans, an equivalent Batf3-dependent DC subset characterized by 
expression of CD11c, CD141, Clec9a/DNGR-1 and XCR1 has been identified in 
peripheral blood and lymphoid organs (14). 
Immunotherapy of cancer is currently being revolutionized by the use of 
immunomodulatory monoclonal antibodies (mAbs). Interaction of PD-1 (CD279), on 
activated and exhausted lymphocytes, with its ligands (PD-L1 or PD-L2, expressed on 
antigen-presenting DCs and tumor cells) downmodulates T cell signaling (15, 16). 
Interference with these interactions using mAbs to PD-1 or PD-L1 has proved effective 
in cancer patients with metastatic melanoma, renal cell carcinoma, non-small lung 
cancer, bladder cancer, head and neck cancer, and other malignancies (17). In addition, 
stimulation of the costimulatory receptor on activated T lymphocytes CD137 (4-1BB) 
(18) results in complete tumor rejection in some transplantable tumor models (19). 
These promising findings have led to the clinical development of two anti-CD137 
agents mainly for refractory lymphoma (BMS-663513/Urelumab and PF-05082566; 
NCT01775631, NCT02253992, NCT01307267).  
The anti-PD-1 and anti-CD137 mAbs both induce tumor rejection by synergizing with 
vaccines (20), indicating that their function relies on a preexisting suboptimal CTL 
immune response that, if boosted, results in synergistic effects (1). Herein, we find an 
absolute need for Batf3-dependent DCs in cross-priming of tumor antigens to CTLs that 
subsequently upregulate PD-1 and CD137. This antitumor response can thus be 
manipulated with exogenous immunostimulatory mAbs. In consequence, expansion and 
activation of Batf3-dependent DCs concomitant with anti-CD137 mAb or anti-PD-1 
treatment results in a suitable combined antitumor therapy.  
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RESULTS 
Ineffective antitumor therapy with immunomodulatory mAbs in Batf3
-/-
 mice 
The absence of Batf3 affects the ontogeny and function of CD8
+
 DCs in lymphoid 
organs and CD103
+
 DCs in the periphery, impairing cell-associated cross-presentation 
and the ability to produce IL-12 in response to infectious challenge. The antitumor 
effects of immunostimulatory anti-PD-1 and anti-CD137 mAbs are contingent on an 
already present baseline immune response, which is rescued and amplified by treatment. 
Based on the proposed role for Batf3-dependent DCs in immune-surveillance (6), we 
hypothesized that the preexisting immune response rescued by the immunostimulatory 
mAbs might be mediated by Batf3-dependent cross-priming. Grafted MC38-derived 
tumors were lethal in C57Bl/6 WT and Batf3-deficient mice, with slightly faster 
progression in Batf3
-/-
 mice (Fig. 1A). In WT mice, tumor growth was delayed or 
curtailed by a course of treatment with anti-PD-1 or anti-CD137 mAbs, starting on day 
4 after tumor cell inoculation. Combination treatment with both mAbs had a synergistic 
effect on their antitumor action (Fig. 1A and 1B), as previously reported in in other 
tumor models (21). The antitumor efficacy of anti-CD137 and anti-PD-1 mAbs, used 
alone or in combination, was abolished in Batf3
-/-
 mice (Fig. 1A and 1B), suggesting 
that Batf3-dependent DCs are responsible for the baseline immune response that is 
potentiated by immunostimulatory mAbs, as Batf3
-/-
 mice only present some functional 
defects in CD8
+
 resident DC or CD103
+
 migratory DC (6, 7, 12). 
We explored whether the ability of Batf3-dependent DCs to specifically provide IL-12 
that boosts CTL function (8, 13) could underlie the advantage of Batf3-dependent DCs 
to mediate basal antitumor response. We analyzed the ability of intratumorally injected 
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IL-12 to rescue the antitumor effect of systemic anti-CD137 mAb in the absence of 
Batf3. Repetitive injections of recombinant IL-12 in tumor lesions clearly potentiated 
the antitumor effects of systemic anti-CD137 mAb in WT mice, leading to rejection of 
most of the tumors (Fig. 1C). In stark contrast, no therapeutic effect was seen in 
identically treated Batf3
-/-
 mice (Fig. 1C). Administration of IL-12 is thus unable to 
compensate the loss of a key function of Batf3-dependent DCs in the synergy with 
immunostimulatory anti-CD137 mAb. 
 
Impaired ability of Batf3
-/-
 DCs to cross-prime CTLs against tumor antigens 
To investigate the possible involvement of deficient cross-presentation in the non-
responsiveness of Batf3
-/-
 mice to anti-PD-1 and anti-CD137 mAbs, we analyzed the 
ability of CD11c
+
 DCs to cross-present tumor-associated antigens to CD8
+
 T cells ex 
vivo. For these experiments, we used MC38 cells transfected to express ovalbumin 
(OVA) as a surrogate tumor antigen (22). Two days after tumor-cell grafting, CD11c
+
 
DCs from tumor-draining LNs were magnetically sorted and cocultured at different 
ratios with OT-I OVA-specific CD8
+
 T cells. At all ratios tested, OT-I T cells 
cocultured with DCs from Batf3
-/-
 mice produced markedly lower levels of intracellular 
and secreted IFNγ than cells cocultured with WT DCs (Fig. 2, A and B), and also 
showed impaired proliferation (Fig. 2C), although there was some remaining cross-
priming activity by Batf3
-/-
 DC. 
To further inquire the DC subsets responsible for tumor cross-priming in WT and Batf3
-
/-
 mice, we FACS-sorted DC subsets from MC38-OVA tumor-draining LNs into 
resident CD11c
hi
MHC-II
int
CD11b
+
 and CD11c
hi
MHC-II
int
CD8α+, and migratory 
CD11c
int
MHC-II
hi
CD103
+
 and CD11c
int
MHC-II
hi
CD103
-
 DCs and co-cultured them 
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with purified OT-I T cells as above. Notably, only migratory DCs were able to cross-
present and, among these, migratory CD103
+
 DCs demonstrated better ability for cross-
presentation of tumor-associated antigens in a Batf3-dependent fashion (Supplementary 
Fig. S1, A-D). 
We next tested whether deficiency in cross-presentation in the absence of Batf3 results 
in impaired cross-priming to tumor antigens in vivo. We analyzed priming of CD8
+
 T 
cells from the endogenous repertoire to grafted MC38-OVA tumors in WT and Batf3
-/-
 
mice treated or not with anti-CD137. In WT mice, treatment with anti-CD137 mAb 
increased the frequency and numbers of tumor antigen-specific CD8
+
 T cells from the 
endogenous repertoire in the tumor-draining LN (Fig. 2D), correlating with an increased 
effector response upon restimulation with tumor-antigen peptide (Fig. 2E). These 
effects were blocked in the absence of Batf3 (Fig. 2, D and E). Notably, priming of 
CD8
+
 T cells resulted in upregulation of surface PD-1 in CD8
+
 T cells at the tumor-
draining LN in WT mice, and this was impaired in Batf3
-/-
 mice (Fig. 2F). Tumor-
infiltrating lymphocytes (TILs) were basally activated and expressed high PD-1 levels 
that were not further increased by anti-CD137 treatment (Fig. 2G). However, TILs 
expressed much lower levels of PD-1 in Batf3
-/-
 mice (Fig. 2G), which correlates with 
their reduced potential to respond to immunomodulatory mAb therapy. These results 
show that Batf3-dependent DCs are crucial for the priming and concomitant induction 
of targets for immunostimulatory mAbs by tumor-specific CD8
+
 T cells. 
 We further analyzed the response against gp70, a well-described endogenous antigen in 
MC38 colon cancer cells (23). Notably, CD8
+
 TILs specific for gp70 were increased in 
a Batf3-dependent fashion upon anti-CD137 and anti-PD-1 mAb treatment, as detected 
by pentamer staining (Figure 2H). A similar analysis of the response to the Adpgk 
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mutated neoantigen (24) showed some positive responses in WT but not Batf3-deficient 
mice (Supplementary Fig. S2, A and B). 
Priming of CD137
+
 PD1
+
 antigen-specific TILs by activated Batf3-dependent DCs 
We hypothesized that expansion and activation of Batf3-dependent DCs with sFlt3L 
and the TLR3 adjuvant poly-ICLC would synergize with immunostimulatory mAbs to 
enhance priming of tumor-specific CD8
+
 T cells. To extend our results to an alternative 
tumor model, we used B16-OVA melanoma cells grafted subcutaneously. 
Hydrodynamic injection of a plasmid expressing sFlt3L markedly promoted the 
expansion of cross-presenting DCs (Supplementary Fig. S3A). Intratumoral 
administration of poly-ICLC increased some activation markers including CD40 and 
PD-L1 in DCs from the in spleen, tumor and tumor-draining LN, particularly in the 
TLR3-expressing CD103
+
 DCs (Supplementary Fig. S3B-S3D). Immunity to B16-OVA 
was estimated from the number of TILs detected by OVA-MHC-tetramer staining, and 
was almost undetectable in control mice treated with empty vector and intratumoral 
saline buffer (Fig. 3A). Systemic hydrodynamic injection of sFlt3L combined with 
intratumoral injection of poly-ICLC raised a specific antitumor CTL response, and this 
induction was blocked in Batf3
-/-
 mice (Fig. 3A). These events were paralleled by an 
increased frequency of CD137
+
 CD8
+
 T cells in WT mice treated with sFlt3L and poly-
ICLC, and the impairment of this effect in Batf3
-/-
 mice (Fig. 3B). Notably, antigen-
specific TILs showed higher surface expression of PD-1 and CD137 compared with the 
bulk of CD8 infiltrating T cells (Fig. 3C). These results show that expansion and 
activation of Batf3-dependent DCs increases the frequency of primed CD8
+
 T cells that 
upregulate markers of activation and exhaustion and are sensitive to immunostimulatory 
mAb treatment because of the expression of the targets for such agents.  
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Batf3-dependent DC activation enhances antitumor ability of immunomodulatory mAbs 
We next sought to establish how Flt3L- and poly-ICLC-enhanced priming of CD8
+
 T 
cells affects the antitumor efficacy of anti-CD137 and anti-PD-1 mAbs. For this 
analysis we used the B16-OVA model, which in our hands responds weakly or not at all 
to anti-PD-1 or anti-CD137 mAb treatment (Fig. 4, A and B). Hydrodynamic injection 
of sFlt3L was concomitant with tumor inoculation, and intratumoral injection of poly-
ICLC at day 7 was administered with or without anti-PD-1 or anti-CD137 mAbs at days 
4, 7 and 10 after tumor inoculation. The triple combinations retarded tumor progression 
and significantly extended overall survival in WT mice (Fig. 4, A and B) but had no 
significant effect in Batf3
-/-
 mice (Fig. 4, C and D). Furthermore, we found that 
quadruple combination immunotherapy encompassing sFlt3L + poly-ICLC + anti-
CD137 + anti-PD-1 mAbs exerted marked antitumor effects against parental B16F10-
derived melanomas (Supplementary Fig. S4A), while completely eradicated B16-OVA-
derived tumors (Supplementary Fig. S4B). Functional enhancement of Batf3-dependent 
DCs thus cooperates synergistically with anti-CD137 and anti-PD-1 mAbs, indicating 
that baseline Batf3-dependent cross-priming is a key limiting factor that can be targeted 
to enhance antitumor immunity. 
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DISCUSSION 
This study shows the immunodynamic interactions between professional cross-priming 
DCs and immunostimulatory mAbs that target CD137 and PD-1. The observations are 
fully consistent with an essential presentation of tumor antigens to CD8
+
 T cells by 
Batf3-dependent DCs. Both migratory CD103
+
 DCs and LN-resident CD8α+ DCs are 
functionally or ontogenically impaired in Batf3
-/-
 mice (6,7,12), as they are also in Irf8
-/-
 
mice (12). Our results support a model in which at least one of these DC subsets is 
crucial for the basal antitumor response that is amplified by immunostimulatory mAbs.  
Batf3-dependent DC subsets have been identified in the tumor environment, where they 
are functional and even have positive prognostic significance (12). These DCs are 
effective at taking up antigen from tumor cell debris for MHC class I cross-presentation. 
We find that these DCs mediate CTL priming at the malignant tissue or migrate via 
lymphatic afferent vessels to reach the draining LNs and meet naive or central memory 
CD8
+
 T cells. These primed CTLs upregulate surface CD137 and PD-1, making them 
suitable targets for immunostimulatory mAbs. Our results show that expansion and 
activation of Batf3-dependent DCs result in increased antitumor priming and more 
effective tumor rejection in response to immunostimulatory mAbs. The dependency of 
anti-CD137 mAb treatment on DCs was suggested by the decreased efficacy of 
treatment upon depletion of CD11c cells (25). In the case of anti-PD-1 mAb, treatment 
synergizes with vaccines consisting of tumor cells transfected with GM-CSF or Flt3L, 
whose activity depends on attraction and differentiation of DC subsets (26).   
Our data are consistent with the recent results from Gajewski and colleagues, elegantly 
showing that Batf3-dependent CD103
+
 DCs play an important role in regulating the 
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infiltration of T cells in the tumor. Notably, intratumoral injection of cultured Flt3L-
derived DCs rescues the response to anti-CTLA-4 and anti-PD-L1 immunomodulatory 
mAbs in terms of inducing antitumor CTLs and exerting antitumor activity (9). Previous 
studies from the same group had indicated a role for CD8α+ dendritic cells in the 
baseline CTL response to a transplantable melanoma model (27). 
CD103
+
 DCs were recently shown to be responsible not only for priming in the draining 
LN, but also for IL-12-dependent promotion of a productive CD8
+
 T cell response 
locally in the tumor (12, 13), suggesting that expansion and activation of Batf3-
dependent DCs might favor the generation of antitumor responses at several levels. 
Although professional cross-priming DCs have been characterized as key IL-12 
producers in infections and also in the tumor environment (8, 12, 13), we find that 
treatment of tumor-bearing mice with exogenous IL-12 is unable to rescue a key Batf3-
dependent function needed for synergy with immunostimulatory mAbs. Therefore, 
while IL-12 production might be involved in the action of Batf3-dependent DCs, other 
functions of cross-priming DCs are absolutely needed. It is becoming apparent that 
effective anti-CTLA-4 or anti-PD-1 mAb therapy requires the presence of a measurable 
pre-existent CTL response to the tumor mutatome epitopes, both in humans and mice 
(28). It is now crucial to identify whether such responses are caused by direct 
presentation of antigens by tumor cells or by cross-priming of tumor cell-associated 
antigens in the tumor or in the tumor-draining LNs. Our data suggest that basal 
antitumor responses that are amplified by immunostimulatory mAbs have a critical 
requirement for professional cross-priming by DCs. 
The need for cross-priming in the antitumor immune response also indicates possible 
relationships with mechanisms of immunogenic tumor cell death (10). Recent results 
show a crucial role for Batf3-dependent CD103
+
 DCs in priming a CTL response 
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through IL-12 production in the context of tumor cell death induced with paclitaxel (12, 
13). However, doxorubicin-mediated immunogenicity against F244 sarcoma cells is 
Batf3-independent (10) and Batf3-deficient mice are able to reject tumors under 
conditions with exogenously provided IL-12 (11). Therefore the precise role of Batf3-
dependent CD103
+
 DCs may depend on the context of the ongoing baseline immune 
response in the tumor, which will be eventually modulated by the treatment with 
immunostimulatory mAbs. 
Each addition to our knowledge in this area of tumor antigen cross-priming has the 
potential to provide predictive biomarkers for the efficacy of immunostimulatory mAbs, 
since cross-priming against tumor neo-antigens seems to be a key determinant of the 
variable efficacy of these treatments in mice and humans (1, 12, 28). Moreover, more 
effective vaccines could be prepared by immune sorting or targeting these cross-priming 
DC populations or their differentiation in culture from precursors (29).  
Overall, our results raise important pointers for improving therapy with 
immunostimulatory mAbs. The cross-priming function of DCs is essential for the 
therapeutic effect of immunostimulatory mAbs, but the baseline CTL-priming function 
is suboptimal. These observations suggest the potential to devise exogenous or in situ 
tumor vaccination therapies to enhance cross-priming of tumor antigens and thereby 
increase the efficacy of immunostimulatory mAbs. 
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MATERIALS AND METHODS 
 
Mice 
Mice were bred at the CNIC and the CIMA in specific pathogen-free conditions. Batf3
-/-
 
on C57BL/6 background (kindly provided by Dr. Kenneth M. Murphy, Washington 
University, MO, USA) were further backcrossed with C57BL/6 mice at the CNIC to 
establish WT and Batf3
-/-
 cousin colonies from the heterozygotes. Animal studies 
(protocol approval 150/12) were approved by the local ethics committee. All animal 
procedures conformed to EU Directive 2010/63EU and Recommendation 2007/526/EC 
regarding the protection of animals used for experimental and other scientific purposes, 
enforced in Spanish law under Real Decreto 1201/2005.  
 
Cell lines, culture conditions and tissue processing 
MC38, MC38-OVA, B16F10 and B16-OVA cells were cultured in RPMI medium 
(Gibco) supplemented with 10% decomplemented and filtered fetal bovine serum 
(Sigma Aldrich) containing 50 µM β-mercaptoethanol, 100 U/ml penicillin and 100 
µg/ml streptomycin (all from Gibco). MC38 cells were provided by Dr. Karl E. 
Hellström (University of Washington, Seattle) in September 1998. B16F10 cells were 
purchased from the ATCC in June 2006. B16-OVA cells were a kind gift from Dr. 
Lieping Chen in November 2001. These cell lines were authenticated by Idexx Radil 
(Case 6592-2012) in February 2012. MC38-OVA cells were kindly provided by Kees 
Melief (Leiden University Medical Center, Netherlands) in November 2013 and were 
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not further verified. All cell lines were cultured at 37ºC with 5% CO2. Isolated lymph 
nodes (LN) were incubated in collagenase/DNase for 15 minutes at 37ºC, followed by 
mechanical disaggregation using frosted slides. Single cell suspensions were then 
stained for flow cytometry. 
 
Flow cytometry 
Acquisition was performed using a FACS Canto II flow cytometer (BD Biosciences). 
The antibodies used included FITC-conjugated αPD-1 (29F.1A12) and αCD40 (3/23); 
PE-conjugated αCD11b (M1/70), αCD137 (17B5), and αIFNγ (XMG1.2); PrCPCy5.5-
conjugated αCD103 (2E7) and αCD11c (N418); APC-conjugated αCD11b (M1/70), 
αPDL1 (10F.9G2), αCD8 (53-6.7) and αXCR1 (ZET); BV570-conjugated αCD8 (53-
6.7); and BV421-conjugated αCD4 (RM4-5). For identification of epitope-specific T 
cells, PE or Alexa Fluor 647-conjugated H-2K
b
-OVA257-264 tetramer (MBL and NIH 
Tetramer Facility), H-2K
b
-KSPWFTTL pentamer (gp70, Proimmune) or H2-D
b
-
ASMTNMELM dextramer (Adpgk, Immudex) were used. For intracellular staining, 
cells were fixed and permeabilized using Cytofix/Cytoperm buffer and then incubated 
with fluorochrome-conjugated antibodies in PermWash buffer (BD Biosciences). 
 
In vivo tumor experiments 
Cultured tumor cells were trypsinized before reaching confluence and suspended in 
phosphate buffered saline (PBS). Unless specified otherwise, 5 x 10
5
 cells in 50 µl PBS 
were used for inoculation. Cells were injected subcutaneously (s.c.) using 29G syringes 
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into the shaved right flank of 8-12 week-old C57Bl/6 Batf3
-/-
 and WT mice. Tumor size 
was measured twice weekly and calculated as the product of orthogonal diameters. 
Anti-CD137 (1D8) antibody was produced as described (19). Anti-PD-1 (RMP1-14) 
antibody was purchased from BioXcell. Antibodies (100 µg) were administered 
intraperitoneally (i.p.) in PBS on days 4, 7 and 10 after tumor inoculation. Recombinant 
mouse IL-12 (25 ng/dose) (Miltenyi) was administered intratumorally (i.t.) on days 7, 9 
and 11. In experiments involving injection of IL-12, anti-CD137 was administered on 
days 7, 10 and 13. For in vivo DC expansion, 10 µg of sFlt3L-coding plasmid 
(pUMVC3-mFLex, Aldevron) or a control empty plasmid were injected i.v. to achieve 
hydrodynamic liver gene transfer. For in vivo stimulation of DCs, 100 µg poly-ICLC 
(Hiltonol, Oncovir) were injected i.t. on day 7 or when tumors reached 25-50 mm
2
. PBS 
was injected as control.  
 
Ex vivo cross-presentation of surrogate tumor antigen  
To test the ex vivo cross-presentation capacity of LN DCs, sFlt3L plasmid-injected 
mice were bilaterally inoculated s.c. with 2 x 10
6
 MC38-OVA cells. LNs were extracted 
48h later. CD11c
+
 cells were magnetically sorted with CD11c microbeads in an 
AutoMACS Pro Separator (Miltenyi) and further FACS-sorted where indicated. OT-I 
CD8 T lymphocytes were magnetically sorted from the spleens of C57Bl/6 mice using 
CD8 microbeads (Miltenyi). Cell Violet-labeled (Thermo Fisher) OT-I lymphocytes 
were cocultured with Batf3
-/-
 and WT LN-derived CD11c
+
 or FACS-sorted CD11c
+
 
subsets over a range of ratios. SIINFEKL peptide-pulsed DCs served as positive 
controls. After 72 h, culture supernatants were collected and OVA-reactive T cells were 
restimulated ex-vivo with 1 µg/ml SIINFEKL peptide for 5 h, being Brefeldin A (10 
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µg/ml; Sigma-Aldrich) added for the last 4h. Cells were then stained for membrane 
markers before being fixed and permeabilized for staining of intracellular IFN-γ. 
Secreted IFN-γ was measured in culture supernatants with the BD Biosciences OptEIA 
Mouse IFN-γ ELISA kit. 
 
Analysis of T cell priming by tumor antigens 
WT and Batf3
-/-
 mice were inoculated s.c. with 2 x 10
6
 MC38-OVA cells. Mice were 
injected i.p. with 100 µg anti-CD137 or an isotype control at days 5 and 7 after tumor 
inoculation. LNs and tumors were extracted at day 9. LNs were incubated at 37ºC in 
Liberase TL (Roche, 20 minutes) and tumors in Liberase TL/DNase I (30 minutes). 
Then, both LN and tumors were mechanically dissociated through a 70 µm cell strainer 
(Fisher Scientific). Single cell suspensions were stained and analyzed by flow 
cytometry.  
 For OVA- or Adpgk-specific T cell restimulation ex-vivo, single cell 
suspensions from LNs were cultured for 2 h in 10% FBS RPMI medium containing 1 
µg/ml SIINFEKL or ASMTNMELM peptide. Then Brefeldin A was added at a final 
concentration of 10 µg/ml and cells were incubated for 10 h. Cells were stained for 
surface markers, fixed and permeabilized for intracellular IFN-  staining. Samples were 
analyzed by flow cytometry.  
 
Statistical analysis 
Tumor growth data were analyzed with Prism software (GraphPad Software, Inc.). 
Mean diameters of tumors over time were fitted using the formula y = A x e 
(t-t0) 
/ (1 + 
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e
(t-t0)/B
), where t represents time, A the maximum size reached by the tumor and B its 
growth rate. Treatments were compared using the extra sum-of-squares F test. Tumor 
survival was compared with log-rank (Mantel-Cox) tests. All other analyses among 
groups were performed as described in figure legends. 
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FIGURE LEGENDS 
 
Fig. 1. Antitumor therapy with immunomodulatory mAbs is abrogated in Batf3
-/-
 
mice and is not rescued by IL-12 administration.  
WT or Batf3
-/-
 mice were s.c. inoculated with 5 x 10
5
 MC38 cells. (A, B) Mice were 
injected i.p. with 100 µg anti-PD-1 and anti-CD137 mAbs, alone or in combination (100 
µg each), or with vehicle (untreated) on days 4, 7 and 10 after tumor cell inoculation. 
(A) Growth plots of individual tumors. (B) Overall survival charts show pooled results 
from 3 independent experiments with similar results. (C) Tumor-inoculated mice were 
injected i.p. with 100 µg anti-CD137 mAb on days 7, 10 and 13. The indicated groups 
of mice additionally received i.t. injections of recombinant mouse IL-12 or saline on 
days 7, 9 and 11. IL-12 was injected at 25 ng/dose into the tumor nodules. On the left, 
tumor area (mean ± SEM); on the right, overall survival. Fractions indicate the number 
of animals surviving at the end of the protocol. * p < 0.05; ** p < 0.01; *** p < 0.001. 
 
Fig. 2. Reduced ability of Batf3
-/-
 DC to cross-prime CTLs against tumor antigens 
both in steady state and after treatment with anti-CD137 and anti-PD-1 mAbs.  
(A-C) CD11c
+
 DCs from WT and Batf3
-/-
 mice bearing MC38-OVA tumors were 
magnetically sorted from tumor-draining LNs and cocultured (see Methods) with 
purified naïve CD8
+
 OT-I TCR transgenic T cells over a range of DC:T cell ratios. (A) 
Left: representative flow cytometry dot plots of intracellular IFN-γ staining in OT-I T 
cells cultured at a 1:4 DC:T cell ratio. Right: percentages of IFN-γ-positive OT-I T cells 
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at all ratios tested. (B) IFN-γ concentrations in the culture supernatants. (C) Percentages 
of proliferating OT-I cells by dilution of Cell Violet dye (D-F) WT and Batf3
-/-
 mice 
grafted with MC38-OVA cells were treated with anti-CD137 (days 5 and 7) and tumor-
draining LN analyzed on day 9 (see methods). (D) Frequency of H-2K
b
-OVA-tetramer
+
 
cells among CD8
+
 T cells. (E) Intracellular IFN-  production induced by restimulation 
with OVA257-264 peptide in CD8
+
 T cells from tumor-draining LN. (F) PD-1 surface 
staining on tumor-draining LN CD8
+
 T cells. (G) Frequency of PD-1
+
 lymphocytes 
among CD8
+
 TILs in mice treated as in D.  (H) WT and Batf3
-/-
 mice grafted with 
MC38 cells were treated with anti-CD137 and anti-PD-1 mAbs on days 12 and 14 and 
tumor-infiltrating lymphocytes were analyzed on day 16 to detect CD8 T lymphocytes 
specific for gp70 antigen (A-C) Two-way and (D-H) one-way ANOVA with Bonferroni 
post-hoc test. * p < 0.05; ** p< 0.01; *** p < 0.001 
   
 
Figure 3. sFlt3L and poly-ICLC induce a Batf3-dependent increase in the numbers 
of tumor-antigen-specific TILs expressing CD137 and PD-1. 
WT or Batf3
-/-
 mice were inoculated with B16-OVA melanoma cells on day 0, 
concomitant with hydrodynamic gene transfer of sFlt3L or control empty plasmid. On 
day 7, tumors were injected with poly-ICLC or control. Tumors were retrieved and TILs 
analyzed on day 10. (A) H2Kb-OVA257-264 tetramer staining in CD8
+
 TILs. Left: 
Representative plots. Right: Graphs corresponding to a representative experiment (n = 
3) (B) Surface CD137 and PD-1 immunostaining in CD8 TILs. (C) PD-1 and CD137 
surface immunostaining in SIINFEKL tetramer
+
 gated T cells. One-way ANOVA with 
Bonferroni post-hoc test, * p < 0.05; ** p < 0.01; *** p < 0.001. 
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Figure 4. sFlt3L and poly-ICLC do not control the progression of B16-OVA 
derived tumors in Batf3
-/-
 mice. 
WT B16-OVA-bearing mice administered with hydrodynamic gene transfer with sFlt3L 
or control empty plasmid received i.p. injections of anti-CD137 mAb (A) or anti-PD-1 
mAb (B), controlled by vehicle buffer, on days 4, 7 and 10. Poly-ICLC or control was 
administered i.t. on day 7. On the left, tumor areas (mean ± SEM). On the right, overall 
survival. (C-D) Comparison of the combined efficacy of sFlt3L + poly-ICLC with anti-
CD137 mAb (C) or anti-PD-1 (D) in WT and Batf3
-/-
 mice. Graphs represent pooled 
data from 4 (A,C) or 2 (B,D) independent experiments with similar results, for a total of 
10-15 mice per group.  * p < 0.05; ** p < 0.01; *** p < 0.001 
